A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs DNK 333 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Oct 2007 Status changed from in progress to completed
- 24 Aug 2007 Status changed from recruiting to in progress.
- 02 Oct 2006 New trial record.